| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
DN5355 targets amyloid-beta (Abeta) protein and hyperphosphorylated tau protein. It binds to aggregated forms of both pathological proteins. The compound interacts with Abeta fibrils to promote dissociation and binds to tau proteins (including K18 and P301S mutants) as both monomers and aggregates. No IC50 values were reported in the search results .
|
|---|---|
| ln Vitro |
DN5355 inhibits the aggregation of both Abeta and tau proteins. It also disaggregates pre-formed Abeta and tau fibrils in a concentration-dependent manner. In disaggregation assays, DN5355 effectively dissociates pre-formed amyloid fibrils. The compound interacts with Abeta fibrils at specific binding sites to promote dissociation, and binds to tau aggregates (K18 and P301S) as demonstrated by fluorescence shift assays .
|
| ln Vivo |
In the 5XFAD transgenic mouse model of Alzheimer's disease, oral administration of DN5355 significantly reduced cerebral Abeta plaques and hyperphosphorylated tau tangles. DN5355 treatment ameliorated cognitive deficits in these mice, as shown by improved performance in Y-maze spontaneous alternation tests (working memory) and contextual fear conditioning tests (hippocampal-dependent memory) .
|
| Enzyme Assay |
Aggregation and disaggregation assays were performed using thioflavin T (ThT) fluorescence. Abeta or tau (K18) peptides were incubated with or without DN5355 at 37degC for 3-10 days. ThT fluorescence was measured to quantify fibril formation. For disaggregation, pre-formed fibrils were treated with DN5355. The BBB-PAMMA assay assessed blood-brain barrier permeability. The MAP assay identified Abeta-interaction sites. Tau binding was assessed by fluorescence spectroscopy .
|
| Cell Assay |
Thioflavin T (ThT)-based fluorescence assays were used to monitor Abeta and tau aggregation. Abeta or tau peptides were incubated with DN5355 in microplates at 37degC. ThT fluorescence (excitation ~440 nm, emission ~480 nm) was measured at multiple time points. For cell-based studies, the search results did not describe specific cell culture protocols. No cytotoxicity or cell viability assays were detailed .
|
| Animal Protocol |
The 5XFAD transgenic mouse model of Alzheimer's disease was used. Mice were orally administered DN5355 (dose not specified in search results) for a defined treatment period. Following treatment, brains were harvested for immunohistochemical analysis of Abeta plaques and tau tangles. Cognitive function was assessed using Y-maze spontaneous alternation and contextual fear conditioning tests .
|
| ADME/Pharmacokinetics |
The search results did not provide detailed pharmacokinetic parameters (such as Cmax, AUC, half-life, or oral bioavailability) for DN5355. However, the compound is reported to be orally active and is administered orally in vivo. The BBB-PAMPA assay indicates that DN5355 has blood-brain barrier permeability, which is essential for CNS activity in Alzheimer's disease .
|
| Toxicity/Toxicokinetics |
Specific toxicity data for DN5355 were not reported in the search results. The compound is described as a research tool for Alzheimer's disease, and no adverse event profiles, LD50 values, or target organ toxicity information were available. The safety profile in animal models was not detailed in the provided abstracts or product descriptions .
|
| References | |
| Additional Infomation |
DN5355 is a dual-targeting small molecule that modulates both Abeta and tau aggregation pathways, two hallmarks of Alzheimer's disease pathology. It simultaneously inhibits aggregation and promotes disaggregation of both amyloid plaques and neurofibrillary tangles. DN5355 is chemically stable and has shown efficacy in a transgenic mouse model, making it a promising candidate for AD drug development. It is currently in preclinical research stages .
|
| Molecular Formula |
C11H7N3OS2
|
|---|---|
| Molecular Weight |
261.32
|
| CAS # |
937012-09-4
|
| Appearance |
Typically exists as solids at room temperature
|
| SMILES |
[C@]12(C)CC[C@]3([H])[C@@]4(C)CC[C@@H](O[C@@H]5O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]5O)C[C@@]4([H])CC[C@@]3([H])[C@]1([H])CC[C@]2([H])[C@H](C)CCC(=O)NCC([O-])=O.[Na+]
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.8267 mL | 19.1336 mL | 38.2673 mL | |
| 5 mM | 0.7653 mL | 3.8267 mL | 7.6535 mL | |
| 10 mM | 0.3827 mL | 1.9134 mL | 3.8267 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
